CDMO Selection & CMC
CDMO Selection and CMC Strategy for Biotech Programs
Independent CDMO and CRO selection, comparability planning, and CMC regulatory strategy, designed to keep your CMC package aligned with clinical milestones, regulatory expectations, and partnering value.
Looking for a CMC consultant? PXM operators work inside your team.
PXM is a life-science venture and transactions firm. Our senior CMC operators join your leadership team to own CDMO selection, comparability and the CMC package, aligned with your clinical milestones and the diligence investors and partners will run.
See the Operate practiceCMC as a Strategic Discipline, Not a Bottleneck
CMC is where the most preventable program delays happen. Misaligned CDMO selection, late comparability decisions, undefined analytical control strategies, and reactive regulatory positioning routinely add 6 to 18 months to clinical timelines, and erode partnering value at exactly the wrong moment.
PXM's senior operators have led CMC programs from preclinical through commercial filings across small molecules, monoclonal antibodies, ADCs, cell therapies, and gene therapies. We help biotech leadership treat CMC as a strategic discipline: making the right structural decisions early, sequencing investment against clinical and partnering milestones, and ensuring every CDMO, analytical, and regulatory choice supports the program's long-term value.
Whether you are selecting your first CDMO, preparing a CMC section for an IND, or planning the comparability strategy for a process change before pivotal trials, we provide the executive perspective that keeps CMC out of the critical path.
What We Deliver
CMC Development Plan
A phase-appropriate CMC roadmap covering drug substance, drug product, analytical, and stability across IND, Phase 2, pivotal, and BLA / NDA milestones.
CDMO Strategy & Selection
Independent CDMO scouting, capability assessment, RFP design, and contract review to align manufacturing partners with program needs and timelines.
Analytical & Control Strategy
Definition of CQAs, analytical method strategy, specifications, and control strategy aligned with ICH Q8 / Q9 / Q10 / Q11 and modality-specific FDA expectations.
Comparability Strategy
Risk-based comparability planning for process changes, scale-ups, and site transfers, protecting clinical timelines and avoiding bridging studies where possible.
CMC Regulatory Submissions
Strategic input and senior review of CMC sections for IND, IMPD, BLA, and NDA filings, plus support for FDA Type B / Type C CMC meetings.
Partnering & Diligence Readiness
CMC narrative and data-room preparation for licensing, M&A, and Series B+ diligence, positioning your CMC story as a partnering asset, not a liability.
Who This Is For
- Biotech companies building their first CMC strategy ahead of an IND filing
- Programs transitioning from preclinical CDMOs to GMP clinical and commercial supply
- Teams planning process changes, scale-ups, or site transfers between clinical phases
- Companies preparing CMC sections for BLA / NDA submissions or pre-approval inspections
- Founders and CEOs preparing for partnering, licensing, or acquisition diligence
- Investors and boards seeking independent assessment of a portfolio company's CMC posture
How We Work
Assess
Diagnostic of your current CMC program, CDMO relationships, regulatory posture, and gaps against phase-appropriate expectations.
Design
Definition of the CMC strategy, control strategy, and CDMO architecture aligned with clinical and partnering milestones.
Execute
Senior oversight of CDMO selection, comparability planning, analytical development, and CMC regulatory interactions.
Sustain
Ongoing CMC governance through clinical phases, process changes, and regulatory submissions up to commercial readiness.
Frequently Asked Questions
Related Reading
Choosing a US CDMO or CRO in 2026
What the BIOSECURE Act and the FDA PreCheck pilot mean for EU biotechs selecting US manufacturing and clinical partners.
Read moreCDMO Selection Criteria for Biotech
The criteria that actually predict a successful partnership, plus a full FAQ on selection, audits, and transfer risk.
Read moreBIOSECURE Act & FDA PreCheck Readiness
Supply chain exposure mapping, transfer planning, and US facility readiness for programs affected by both policy shifts.
Read moreFDA & CMC Readiness
Guides and insights
What a Clinical Overview Must Contain for an EU Hybrid Application
What the Clinical Overview (Module 2.5) must cover in an EU hybrid application under Article 10(3), how to justify differences from the reference product, and where assessors push back.
Read the guide →Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up
How to build the Clinical Overview for an EU well-established use application under Article 10a: the ten-year test, literature selection, and how to bridge your product to the published evidence.
Read the guide →How to Choose an Independent Clinical Expert for Your EU Dossier
What Article 12 of Directive 2001/83/EC requires from the Clinical and Nonclinical Expert, what to look for when you appoint one, and the questions to ask before they sign.
Read the guide →FDA National Priority Voucher (CNPV): Should You Apply?
What the FDA national priority voucher (CNPV) offers in 2026, how it compares to other expedited programs, and what EU sponsors need ready first.
Read the guide →Your CDMO Just Became a Regulatory Risk: BIOSECURE and FDA PreCheck Explained
The BIOSECURE Act is law and the FDA's PreCheck pilot has named its first participants. Both change how EU biotechs should screen, select, and oversee US CDMOs and CROs.
Read the guide →How to Prepare for an FDA Pre-IND Meeting (and What Most Teams Get Wrong)
A pre-IND meeting is the cheapest regulatory advice a biotech will ever get, and the most commonly wasted. What to ask, what to include in the briefing book, and where teams lose the value.
Read the guide →IND-Enabling Studies: What a First-in-Human Package Actually Requires
What IND-enabling studies are, which ones the FDA expects before first-in-human, how long the package takes, and the sequencing decisions that quietly determine your filing date.
Read the guide →CDMO Selection for Biotech: The Criteria That Actually Predict Success
Choosing a CDMO is a regulatory decision, not a procurement one. The criteria that matter, the questions to ask before signing, and the contract terms teams regret leaving out.
Read the guide →5 CMC Strategy Mistakes That Delay IND Filings — And How to Avoid Them
Common chemistry, manufacturing, and controls pitfalls that quietly derail small biotech IND timelines, and the practical fixes that keep programs on track.
Read the guide →3 Regulatory Mistakes That Keep Coming Up in Biotech
After several recent conversations with biotech and digital health teams, a pattern keeps repeating. Not around the science — that's usually strong. It's around regulation.
Read the guide →Bluebird Bio's Three-Year FDA Delay: The CMC Trap That Stalls Gene Therapy Programs
Bluebird Bio almost didn't survive the road to FDA approval — not because the science wasn't there, but because of CMC comparability gaps and pediatric safety signals that weren't built into the development plan. The same patterns are stalling programs today.
Read the guide →UK Biotech Companies: How to Navigate EU and US Market Entry Post-Brexit
Brexit has fundamentally reshaped the regulatory and commercial landscape for UK biotech companies. Navigating parallel pathways across the MHRA, EMA, and FDA requires a new level of strategic coordination — and the companies that adapt fastest will capture the greatest opportunity.
Read the guide →Cell Therapy Companies: Manufacturing May Become Your Biggest Bottleneck
Many biotech teams focus heavily on discovery and clinical data. But regulators are increasingly asking a different question: Can you manufacture your therapy consistently and at scale?
Read the guide →A Regulatory Inflection Point for Biologics – Will You Lead or React?
The FDA's recent announcement signals a meaningful shift in how biologics and ultra-rare disease therapies may be evaluated — including openness to smaller, well-justified data packages.
Read the guide →
Ready to discuss your program?
Speak with a senior PXM operator about your cdmo selection & cmc readiness strategy.